Citations

Showing 10 of 108152 citations.

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis
Sidana, Surbhi , Sidiqi, M Hasib , Lacy, Martha Q. , Muchtar, Eli , Dingli, David , Hayman, Suzanne R. , Gonsalves, Wilson I. , Kapoor, Prashant , Warsame, Rahma , Kourelis, Taxiarchis , Kumar, Shaji , Dispenzieri, Angela , Gonsalves, Wilson , Leung, Nelson , Warsame, Rahma , Kourelis, Taxiarchis , Wolf, Robert C, Gertz, Morie A , Muchtar, E , Sidiqi, M Hasib , Sidana, Surbhi , Dingli, David , Dispenzieri, Angela , Buadi, Francis K. , Leung, Nelson , Wolf, Robert Christian , Hogan, William J. , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | June 29, 2019 | Volume: 94 | Issue: 9 | Pages: 1020-1026

10.1002/ajh.25566 | PMID 31254301 Get It

Abstract In appropriately selected patients with AL amyloidosis, autologous stem cell transplant (ASCT) is an established treatment modality with excellent outcomes and decreasing transplant related mortality (TRM) over time. We report on 15‐year overall survival (OS) in 159 patients undergoing ASCT from 1996 to 2003, with median follow up of 17.1 years. Day 100 TRM was 13.2% (n = 21). The OS of ≥15 years was observed in 30% (47/159) of patients. Patients surviving ≥15 years were younger (53 vs 56 years, P = .02), less likely to have lambda as the involved light chain (62% vs 78%, P = .03) and were less likely to have heart involvement (32% vs 56%, P = .005). Median OS of patients with heart involvement vs not was 4.0 vs 11.1 years, P = .006 and actuarial 15‐year OS was 23% vs 43%, respectively. A higher proportion of patients with OS ≥15 years received full‐dose melphalan conditioning (81% vs 61%, P = .01), and achieved day 100 complete response (CR) (64% vs 24%, P < .001). Median OS amongst patients who achieved CR vs not was 19.3 vs 5.4 years, P < .001. Heart involvement, receiving full‐dose melphalan and achieving CR remained independent predictors of OS. AL amyloidosis and related complications were the cause of death in 52% of patients overall (1‐5 years post‐transplant: 81%; 5‐10 years: 62% and 10‐15 years: 55%). These results reinforce the key role of ASCT in AL amyloidosis. With improvements in TRM and more options for relapsed disease, we expect the long‐term survival post‐transplant to improve significantly in the future.
Effect of fixed-setting versus programmable valve on incidence of shunt revision after ventricular shunting for idiopathic normal pressure hydrocephalus
Rinaldo, Lorenzo , Elder, Benjamin D. , Bhargav, Adip G. , Nesvick, Cody L. , Lanzino, Giuseppe

Mayo Clinic

Journal of Neurosurgery | June 29, 2019 | Volume: 133 | Issue: 2 | Pages: 564-572

10.3171/2019.3.jns183077 | PMID 31174190 Get It

OBJECTIVEAlthough ventricular shunting is an effective therapy for idiopathic normal pressure hydrocephalus (iNPH), the effect of shunt valve type on the incidence of revision surgery is not well defined. To address this issue, shunt revision rates between patients with iNPH receiving a fixed-setting valve (FSV) versus a programmable valve (PV) were compared.METHODSPatients with iNPH treated with ventricular shunting between 2001 and 2017 were included for analysis. The incidence of shunt revision was noted and risk factors for revision were identified using a Cox proportional hazards model. Costs associated with admission for ventricular shunt procedures were obtained from the Vizient national database.RESULTSThere were 348 patients included for analysis, with 98 patients (28.1%) receiving a PV. Shunt revision occurred in 73 patients (21.0%), with 12 patients (3.4%) undergoing multiple revisions. Overall revision rates were lower in patients receiving a PV (13.3% vs 24.0%; p = 0.027), as was the incidence of multiple revisions (0.0% vs 4.8%; p = 0.023). Patients with initial placement of an FSV were also more likely to undergo valve exchange during follow-up (12.4% vs 2.0%; p = 0.003). Patients with a PV were less likely to undergo revision due to persistent symptoms without obstruction (2.0% vs 8.8%; p = 0.031) and distal obstruction (1.0% vs 6.8%; p = 0.030). In a multivariate Cox proportional hazards model, initial placement of a PV was associated with reduced risk of revision due to persistent symptoms without obstruction (OR 0.27, 95% CI 0.04–0.93; p = 0.036). PVs were associated with more frequent shunt series (1.3 vs 0.6; p < 0.001) and head CT scans (3.6 vs 2.7; p = 0.038) during follow-up. There was no significant difference in mean total costs between patients receiving an FSV and a PV ($24,282.50 vs $24,396.90; p = 0.937).CONCLUSIONSThe authors’ results suggest that PVs lead to reduced rates of shunt revision in patients with iNPH, and decreased risk of revision due to persistent symptoms of iNPH, thereby justifying the higher upfront cost of PVs despite similar overall treatment costs between these devices.
The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies
Werneburg, Nathan W., Smoot, Rory L. , Werneburg, Nathan, Smoot, Rory L , Gores, Gregory J.

Mayo Clinic

Gene Expression | June 28, 2019 | Volume: 20 | Issue: 1 | Pages: 67-74

10.3727/105221619x15617324583639 | PMID 31253203 Get It

The Hippo pathway and its effector protein YAP (a transcriptional coactivator) have been identified as important in the biology of both hepatocellular carcinoma and cholangiocarcinoma. First identified as a tumor suppressor pathway in Drosophila , the understanding of the mammalian YAP signaling and its regulation continues to expand. In its “on” function, the canonical regulatory Hippo pathway, a well-described serine/threonine kinase module, regulates YAP function by restricting its subcellular localization to the cytoplasm. In contrast, when the Hippo pathway is “off,” YAP translocates to the nucleus and drives cotranscriptional activity. Given the role of Hippo/YAP signaling in hepatic malignancies, investigators have sought to target these molecules; however, standard approaches have not been successful based on the pathways’ negative regulatory role. More recently, additional regulatory mechanisms, such as tyrosine phosphorylation, of YAP have been described. These represent positive regulatory events that may be targetable. Additionally, several groups have identified potentiating feed-forward signaling for YAP in multiple contexts, suggesting other experimental therapeutic approaches to interrupt these signaling loops. Herein we explore the current data supporting alternative YAP regulatory pathways, review the described feed-forward signaling cascades that are YAP dependent, and explore targeting strategies that have been employed in preclinical models of hepatic malignancies.
Commentary
Murray, David , Murray, David L.

Mayo Clinic

Clinical Chemistry | June 28, 2019 | Volume: 65 | Issue: 7 | Pages: 837-838

10.1373/clinchem.2019.302901 | PMID 31253609 Get It

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities
Salmi, Liz , Freeman‐Daily, Janet , Utengen, Audun , Dizon, Don S. , Blotner, Charlie , Cooke, David T. , Sparacio, Dee, Staley, Alicia C. , Young, Colleen , Young, Colleen D , Utengen, Audun , Katz, Matthew S. , Anderson, Patricia F , Thompson, Michael A. , Fisch, Michael , Attai, Deanna J.

Mayo Clinic

JCO Clinical Cancer Informatics | June 28, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-10

10.1200/cci.18.00124 | PMID 31251658 Get It

Twitter use has increased among patients with cancer, advocates, and oncology professionals. Hashtags, a form of metadata, can be used to share content, organize health information, and create virtual communities of interest. Cancer-specific hashtags modeled on a breast cancer community, #bcsm, led to the development of a structured set of hashtags called the cancer tag ontology. In this article, we review how these hashtags have worked with the aim of describing our experience from 2011 to 2017. We discuss useful guidelines for the development and maintenance of health-oriented communities on Twitter, including possible challenges to community sustainability and opportunities for future improvement and research.
Rapid Antimicrobial Susceptibility Testing of Patient Urine Samples Using Large Volume Free-Solution Light Scattering Microscopy
Mo, Manni , Yang, Yunze , Zhang, Fenni , Jing, Wenwen , Iriya, Rafael , Popovich, John, Grys, Thomas E. , Haydel, Shelley E. , Tao, Nongjian , Wang, Shaopeng , Grys, Thomas, Zhang, Fenni , Haydel, Shelley E , Grys, Thomas E , Popovich, John, Wang, Shaopeng , Jing, Wenwen

Mayo Clinic

Analytical Chemistry | June 28, 2019 | Volume: 91 | Issue: 15 | Pages: 10164-10171

10.1021/acs.analchem.9b02174 | PMID 31251566 Get It

Cardiac rehabilitation delivery in low/middle-income countries
Pesah, Ella, Turk-Adawi, Karam , Supervía, Marta , Britto, Raquel Rodrigues , Ding, Rongjing , Babu, Abraham Samuel , Sadeghi, Masoumeh , Cuenza, Lucky , Santos, Claudia Anchique, Heine, Martin , Oh, Paul , Grace, Sherry L. , Britto, Raquel , Grace, Sherry L , Turk-Adawi, Karam , López-Jiménez, Francisco , Derman, Wayne Elton , Babu, Abraham Samuel

Mayo Clinic

Heart | June 28, 2019 | Volume: 105 | Issue: 23 | Pages: 1806-1812

10.1136/heartjnl-2018-314486 | PMID 31253695 Get It

Objective Cardiac rehabilitation (CR) availability, programme characteristics and barriers are not well-known in low/middle-income countries (LMICs). In this study, they were compared with high-income countries (HICs) and by CR funding source. Methods A cross-sectional online survey was administered to CR programmes globally. Need for CR was computed using incident ischaemic heart disease (IHD) estimates from the Global Burden of Disease study. General linear mixed models were performed. Results CR was identified in 55/138 (39.9%) LMICs; 47/55 (85.5% country response rate) countries participated and 335 (53.5% programme response) surveys were initiated. There was one CR spot for every 66 IHD patients in LMICs (vs 3.4 in HICs). CR was most often paid by patients in LMICs (n=212, 65.0%) versus government in HICs (n=444, 60.2%; p<0.001). Over 85% of programmes accepted guideline-indicated patients. Cardiologists (n=266, 89.3%), nurses (n=234, 79.6%; vs 544, 91.7% in HICs, p=0.001) and physiotherapists (n=233, 78.7%) were the most common providers on CR teams (mean=5.8±2.8/programme). Programmes offered 7.3±1.8/10 core components (vs 7.9±1.7 in HICs, p<0.01) over 33.7±30.7 sessions (significantly greater in publicly funded programmes; p<0.001). Publicly funded programmes were more likely to have social workers and psychologists on staff, and to offer tobacco cessation and psychosocial counselling. Conclusion CR is only available in 40% of LMICs, but where offered is fairly consistent with guidelines. Governments should enact policies to reimburse CR so patients do not pay out-of-pocket.
Type 3 Inositol 1,4,5‐Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma
Ueasilamongkol, Pimwipa, Khamphaya, Tanaporn , Guerra, Mateus T. , Rodrigues, Michele Ângela , Gomes, Dawidson Assis , Kong, Yong , Trampert, David C. , Ananthanarayanan, Meenakshisundaram, Bañales, Jesús M. , Roberts, Lewis R. , Nathanson, Michael H. , Weerachayaphorn, Jittima , Roberts, Lewis R , Banales, Jesus M , Wei, Wei , Jain, Dhanpat , Farshidfar, Farshad

Mayo Clinic

Hepatology | June 28, 2019 | Volume: 71 | Issue: 2 | Pages: 583-599

10.1002/hep.30839 | PMID 31251815 Get It

Cholangiocarcinoma (CCA) is the second most common malignancy arising in the liver. It carries a poor prognosis, in part because its pathogenesis is not well understood. The type 3 inositol 1,4,5‐trisphosphate receptor (ITPR3) is the principal intracellular calcium ion (Ca2+) release channel in cholangiocytes, and its increased expression has been related to the pathogenesis of malignancies in other types of tissues, so we investigated its role in CCA. ITPR3 expression was increased in both hilar and intrahepatic CCA samples as well as in CCA cell lines. Deletion of ITPR3 from CCA cells impaired proliferation and cell migration. A bioinformatic analysis suggested that overexpression of ITPR3 in CCA would have a mitochondrial phenotype, so this was also examined. ITPR3 normally is concentrated in a subapical region of endoplasmic reticulum (ER) in cholangiocytes, but both immunogold electron microscopy and super‐resolution microscopy showed that ITPR3 in CCA cells was also in regions of ER in close association with mitochondria. Deletion of ITPR3 from these cells impaired mitochondrial Ca2+ signaling and led to cell death. Conclusion: ITPR3 expression in cholangiocytes becomes enhanced in CCA. This contributes to malignant features, including cell proliferation and migration and enhanced mitochondrial Ca2+ signaling.
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Ahn, Kwang Woo , Hu, Zhen‐Huan , Volpe, Virginia O. , Antin, Joseph H. , Sorror, Mohamed L. , Press, Oliver W. , Pidala, Joseph, Negrin, Robert S., Uberti, Joseph P., Agura, Edward, Nash, Richard A. , Mehta, Jayesh, Forman, Stephen J. , Langston, Amelia , Hale, Gregory A., Marks, David I. , Ganguly, Sid, Reshef, Ran , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Cahn, Jean‐Yves, Solh, Melhem , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Aljurf, Mahmoud , Schouten, Harry C. , Hill, Brian T. , Pawarode, Attaphol , Kindwall‐Keller, Tamila L. , Saba, Nakhle S. , Copelan, Edward A. , Nathan, Sunita , Beitinjaneh, Amer , Černý, Jan , Wirk, Baldeep , Olsson, Richard F. , Bashey, Asad, Sobecks, Ronald , Alyea, Edwin P. , Saber, Wael , Brown, Jennifer R. , Hogan, William, Kharfan-Dabaja, Mohamed A., Saad, Ayman , Press, Oliver , Olsson, Richard F , Reshef, Ran , Kim, Haesook T. , Davids, Matthew S. , Shadman, Mazyar , Hogan, William J. , Devine, Steven M. , McGuirk, Joseph P. , Giralt, Sergio , Perales, Miguel‐Angel , Battiwalla, Minoo , Gale, Robert Peter , Hamadani, Mehdi , Bacher, Ulrike , Lazarus, Hillard M. , Cahn, Jean‐Yves , Ghosh, Nilanjan , Savani, Bipin N. , Grunwald, Michael R. , Yared, Jean A. , Nishihori, Taiga , Chhabra, Saurabh , Gergis, Usama , Popat, Uday R , Sorror, Mohamed

Mayo Clinic

Clinical Cancer Research | June 28, 2019 | Volume: 25 | Issue: 16 | Pages: 5143-5155

10.1158/1078-0432.ccr-18-3988 | PMID 31253630 Get It

Abstract Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Experimental Design: We performed a retrospective analysis of outcomes of 606 patients with CLL who underwent RIC allogeneic HCT between 2008 and 2014 reported to the Center for International Blood and Marrow Transplant Research. Results: On the basis of multivariable models, disease status, comorbidity index, lymphocyte count, and white blood cell count at HCT were selected for the development of prognostic model. Using the prognostic score, we stratified patients into low-, intermediate-, high-, and very-high-risk [4-year progression-free survival (PFS) 58%, 42%, 33%, and 25%, respectively, P &lt; 0.0001; 4-year overall survival (OS) 70%, 57%, 54%, and 38%, respectively, P &lt; 0.0001]. We also evaluated karyotypic abnormalities together with del(17p) and found that del(17p) or ≥5 abnormalities showed inferior PFS. Using a multivariable model, we classified cytogenetic risk into low, intermediate, and high (P &lt; 0.0001). When the prognostic score and cytogenetic risk were combined, patients with low prognostic score and low cytogenetic risk had prolonged PFS (61% at 4 years) and OS (75% at 4 years). Conclusions: In this large cohort of patients with previously treated CLL who underwent RIC HCT, we developed a robust prognostic scoring system of HCT outcomes and a novel cytogenetic-based risk stratification system. These prognostic models can be used for counseling patients, comparing data across studies, and providing a benchmark for future interventions. For future study, we will further validate these models for patients receiving targeted therapies prior to HCT.
Postsurgical thrombotic microangiopathy: Case series and review of the literature
Sridharan, Meera , Hook, C. Christopher , Sridharan, Meera , Leung, Nelson , Winters, Jeffrey L. , Go, Ronald S.

Mayo Clinic

European Journal of Haematology | June 28, 2019 | Volume: 103 | Issue: 4 | Pages: 307-318

10.1111/ejh.13284 | PMID 31251415 Get It

AbstractObjectivesDescribe the clinical presentation, treatment, and outcomes of postsurgical thrombotic microangiopathy (TMA).MethodsIn this retrospective study, records of individuals diagnosed with TMA developing within 30 days of a surgical procedure at Mayo Clinic from 2000 to 2016 were reviewed. Available literature regarding postsurgical TMA was comparatively reviewed.ResultsTwenty patients were diagnosed with TMA developing within 30 (median 6.5, range (1‐28)) days) following a procedure. Preceding procedures included orthopedic (n = 4), vascular (n = 4), abdominal (n = 8), thoracic (n = 2), and other (n = 2). Review of the literature identified 65 patients with postsurgical TMA and cardiovascular procedures were the most common preceding surgery. The majority of patients in the current cohort and literature were treated with therapeutic plasma exchange (TPE). Among the evaluable patients in the current cohort, 100% demonstrated response to TPE; however, 25% required the addition of other therapy including eculizumab to maintain a response 80% of patients in the literature demonstrated a response to TPE.ConclusionsAlthough rare, early recognition and treatment of postsurgical TMA can lead to good outcomes. More research is necessary to determine the underlying pathophysiology and optimal treatment for postsurgical TMA.